Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Destino, Lauren ^a   Sutton, Deanna A ^b   Helon, Anna L ^a   Havens, Peter L ^a   Thometz, John G ^a   Willoughby Jr , Rodney E ^a   Chusid, Michael J ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TERBINAFINE; VANCOMYCIN; VORICONAZOLE;

AGRICULTURE; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; DEBRIDEMENT; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMUR; FLUIDS, EXCRETA AND SECRETIONS; FUNGUS IDENTIFICATION; HUMAN; HYPHOMYCETES; INJURY; KNEE INJURY; LONG TERM CARE; MALE; MYCELIOPHTHORA THERMOPHILA; NONHUMAN; OSTEOMYELITIS; PRESCHOOL CHILD;

CHILD, PRESCHOOL; HUMANS; KNEE INJURIES; MALE; MITOSPORIC FUNGI; MYCOSES; OSTEOMYELITIS; PYRIMIDINES; TRIAZOLES;

EID: 33749571119     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-21     Document Type: Article

References (18)

1. CAN O: The genus Myceliophthora. Persoonia 1977, 9:401-408.
2. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. Volume NCCLS document M38-A. Wayne, PA, Clinical Laboratory Standards Institute; 2002.
3. Ajello L: Hyalohyphomycosis and phaeohyphomycosis: two global disease entities of public health importance. Eur J Epidemiol 1986, 2:243-251.
4. Rinaldi MG: Phaeohyphomycosis. Dermatol Clin 1996, 14:147-153.
5. Silveira F, Nucci M: Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opin Infect Dis 2001, 14:679-684.
6. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002, 34:467-476.
7. Bourbeau P, McGough DA, Fraser H, Shah N, Rinaldi MG: Fatal disseminated infection caused by Myceliophthora thermophila, a new agent of mycosis: case history and laboratory characteristics. J Clin Microbiol 1992, 30:3019-3023.
8. Farina C, Gamba A, Tambini R, Beguin H, Trouillet JL: Fatal aortic Myceliophthora thermophila infection in a patient affected by cystic medial necrosis. Med Mycol 1998, 36:113-118.
9. Tekkok IH, Higgins MJ, Ventureyra EC: Posttraumatic gas-containing brain abscess caused by Clostridium perfringens with unique simultaneous fungal suppuration by Myceliophthora thermophila: case report. Neurosurgery 1996, 39:1247-1251.
10. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC: Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003, 46:233-236.
11. Gupta AK, Taborda PR, Sanzovo AD: Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 2002, 40:529-534.
12. Howden BP, Slavin MA, Schwarer AP, Mijch AM: Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003, 22:111-113.
13. Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C, Karthaus M, Fatkenheuer G, Bethe U, Tintelnot K, Cornely OA: Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004, 83:394-397.
14. Ryder NS, Leitner I: Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001, 39:91-95.
15. Gupta AK, Adamiak A, Cooper EA: The efficacy and safety of terbinafine in children. J Eur Acad Dermatol Venereol 2003, 17:627-640.
16. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002, 21:240-248.
17. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N: Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
18. Taketomo C, Hodding J, Kraus D: Pediatric Dosage Handbook 12th edition. Hudson, Ohio, Lexi-Comp; 2006.